Also known as Laronde and Senda Biosciences.
None yet. When a new project in the record names Sail Biomedicines as owner, partner or investor, it shows here.
Advance lead in vivo CAR‑T program to reset the immune system for immune‑mediated disease; $785M initial funding, $140M milestones, and a $2.58B acquisition option.
